Factors influencing the release kinetics of drug nanocrystal-loaded pellet formulations

Drug Development and Industrial Pharmacy

Volumn 39, Issue 5, 2013, Pages 762-769

  Möschwitzer, Jan P ^a,b   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Medizinische Chemie   (Germany)

Author keywords

Downstream processing; High pressure homogenization; Layering; Matrix cores; Nanosuspension; Particle size reduction

Indexed keywords

CHITOSAN; HYDROCORTISONE ACETATE; HYDROXYPROPYLMETHYLCELLULOSE; NANOCRYSTAL; POLYVINYL ALCOHOL; POVIDONE;

ARTICLE; DOWNSTREAM PROCESSING; DRUG COATING; DRUG PELLET; DRUG RELEASE; DRUG STRUCTURE; HYDROGEL; LIGHT INTENSITY; MOLECULAR WEIGHT; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; REFRACTION INDEX; SCANNING ELECTRON MICROSCOPY; SPHERONIZATION; WATER CONTENT; ZETA POTENTIAL;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG CARRIERS; DRUG IMPLANTS; HYDROCORTISONE; NANOPARTICLES; PARTICLE SIZE;

EID: 84875902399     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.702347     Document Type: Article

References (24)

1. Charman SA Charman WN. (2003). Oral modified-release delivery systems. In: Rathbone MJ, Hadgraft J, Roberts MS, editor. Modified-Release Drug Delivery Technology. Marcel Dekker, 1-10.
2. Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18:113-120.
3. Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3-19.
4. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785-796.
5. Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631-644.
6. Merisko-Liversidge E, Liversidge GG. (2011). Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorlywater soluble compounds using wet media milling technology. Adv Drug Deliv Rev, 63:427-440.
7. Vergote GJ, Vervaet C, Van Driessche I, Hoste S, De Smedt S, Demeester J et al. (2001). An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. Int J Pharm, 219:81-87.
8. Lee J. (2003). Drug nano- and microparticles processed into solid dosage forms: Physical properties. J Pharm Sci, 92:2057-2068.
9. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. (2005). Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm, 299:167-177.
10. Chaubal MV, Popescu C. (2008). Conversion of nanosuspensions into dry powders by spray drying: A case study. Pharm Res, 25:2302-2308.
11. Lee J, Cheng Y. (2006). Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release, 111:185-192.
12. Ho H, Lee J. (2012). Redispersible drug nanoparticles prepared without dispersant by electro-spray drying. Drug Dev Ind Pharm, 38:744-751.
13. Möschwitzer J, Müller, RH, (eds). (2004). From the drug nanocrystal to the final mucoadhesive oral dosage form. Proceedings of APV Int. Meeting on Pharm., Biopharm. and Pharm. Technology, Nuremberg, 2004.
14. Pinto JF, Müller RH. (1999). Pellets as carriers of solid lipid nanoparticles (SLN™) for oral administration of drugs. Die Pharmazie, 54:506-509.
15. Möschwitzer J, Müller RH. (2006). Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm, 62:282-287.
16. Kayaert P, Anné M, Van den Mooter G. (2011). Bead layering as a process to stabilize nanosuspensions: Influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads. J Pharm Pharmacol, 63:1446-1453.
17. Wang P, Luo Q, Miao Y, Ying L, He H, Cai C, et al. Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. Drug Dev Ind Pharm, 1-10. DOI: 10.3109/03639045.2011.650647 (published online first).
18. EMA. (2004). Scientific discussion on Emend. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion- Variation/human/000527/WC500026538.pdf.
19. Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R. (2008). Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm, 34:1209-1218.
20. Chen X, Matteucci ME, Lo CY, Johnston KP, Williams RO 3rd. (2009). Flocculation of polymer stabilized nanocrystal suspensions to produce redispersible powders. Drug Dev Ind Pharm, 35:283-296.
21. Tromm A, Möllmann H, Barth J, Hochhaus G, Krieg M, Bigalke C et al. (2001). Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J Clin Pharmacol, 41:536-541.
22. Gardner RC. (1976). Pharmacotherapy of inflammatory bowel disease. Am J Hosp Pharm, 33:831-838.
23. Rasenack N, Hartenhauer H, Müller BW. (2003). Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int J Pharm, 254:137-145.
24. Krause KP, Müller RH. (2001). Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. Int J Pharm, 214:21-24.